The Biomarker: Melanoma

Sanjiv S. Agarwala, MD
Video Categories: The Biomarker

PMO is pleased to offer the department “The Biomarker” to discuss the identification of biomarkers in patients with cancer and the prognostic/predictive impact and clinical decision-making implications of that marker. This month, we focus on KIT mutations in melanoma patients. Dr Sanjiv Agarwala provides his insights on this provocative topic.
December 3, 2013

Management of Patients with Basal Cell Carcinoma not Eligible for Surgery or Radiation

In this second clinical commentary entitled, Management of Patients with Basal Cell Carcinoma not Eligible for Surgery or Radiation, Joel Claveau, MD, CSPQ, FRCPC; Dirk Schadendorf, MD; Nicole Basset-Seguin, MD, PhD and Aleksandar Sekulic, MD, PhD discuss the need for new treatment options in the care of basal cell carcinoma [ Read More ]

December 12, 2016

New Effective Targets

Sunil Verma, MD, MSEd, FRCPC discusses new classes of therapies for HR+ Breast Cancer.